Q4 2024 TG Therapeutics Inc Earnings Call Transcript
Key Points
- TG Therapeutics Inc (TGTX) reported U.S. revenues of $310 million for 2024, exceeding their target guidance, indicating strong market performance.
- The company presented positive data from the enhanced trial, demonstrating the safety of a 30-minute maintenance infusion for BRIUMVI.
- BRIUMVI's five-year follow-up data showed 92% of patients were free from disability progression, with a low annualized relapse rate.
- The company expanded its patent portfolio, securing protection for BRIUMVI through 2042, strengthening its competitive position.
- TG Therapeutics Inc (TGTX) is exploring new markets, including Myasthenia gravis, and developing a subcutaneous formulation of BRIUMVI, which could expand their market reach.
- The company faces competition from new entrants in the market, which could impact BRIUMVI's market share.
- There is uncertainty regarding the final design and dosing regimen for the subcutaneous BRIUMVI trial, which could delay its development.
- The cost of goods sold to partners outside the U.S. impacts the company's gross margin unfavorably.
- Enrollment for the phase one study of azer-cel in progressive forms of multiple sclerosis has been slow, potentially delaying results.
- The company anticipates increased operating expenses in 2025, which could impact profitability if not managed effectively.
Greetings and welcome to the TG Therapeutics fourth quarter and full year conference call and webcast. (Operator Instructions). As a reminder, this conference is being recorded.
It's all my pleasure to turn the call over to Chief Communications Officer, Jenna Bosco. Please go ahead.
Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the fourth quarter and full year 2024 financial results are Michael Weiss, our Chairman and Chief Executive Officer, Adam Waldman, our Chief Commercialization Officer, and Sean Power, our Chief Financial Officer.
Following our Safe Harbor Statement, Mike will provide an overview of our corporate developments. Adam will share an update on our commercialization efforts, and Sean will give a summary of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I'd like to remind everyone that we will be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
